Table 2.

Relationship between clinical parameters and immunoexpression of PDGF and PDGFR in OSCC patients.

Variables	N	PDGF			PDGFRA			PDGFRB
		Low	High	p-Value	Low	High	p-Value	Low	High	p-Value
Gender
Male	57	25 (43.9%)	32 (56.1%)	0.773	33 (57.9%)	24 (42.1%)	0.710	35 (61.4%)	22 (38.6%)	0.184
Female	6	3 (50.0%)	3 (50.0%)		3 (50.0%)	3 (50.0%)		2 (33.3%)	4 (66.7%)
Age
<54	35	17 (48.6%)	18 (51.4%)	0.461	21 (60.0%)	14 (40.0%)	0.608	23 (65.7%)	12 (34.3%)	0.208
≥54	28	11 (39.9%)	17 (60.7%)		15 (53.6%)	13 (46.4%)		14 (50.0%)	14 (50.0%)
T stage
T1-2	14	8 (57.1%)	6 (42.9%)	0.278	10 (71.4%)	4 (28.6%)	0.221	9 (64.3%)	5 (35.7%)	0.632
T3-4	49	20 (40.8%)	29 (59.2%)		26 (53.1%)	23 (46.9%)		28 (57.1%)	21 (42.9%)
N status
N0	36	21 (58.3%)	15 (41.7%)	0.010 *	26 (72.2%)	10 (27.8%)	0.005 **	26 (72.2%)	10 (27.8%)	0.012 *
N+	27	7 (25.9%)	20 (74.1%)		10 (37.0%)	17 (63.0%)		11 (40.7%)	16 (59.3%)
Stage
I-II	7	4 (57.1%)	3 (42.9%)	0.473	5 (71.4%)	2 (28.6%)	0.418	5 (71.4%)	2 (28.6%)	0.469
III-IV	56	24 (42.9%)	32 (57.1%)		31 (55.4%)	25 (44.6%)		32 (57.1%)	24 (42.9%)
Lymphovascular invasion
No	51	24 (47.1%)	27 (52.9%)	0.389	31 (60.8%)	20 (39.2%)	0.229	33 (64.7%)	18 (35.3%)	0.047 *
Yes	12	4 (33.3%)	8 (66.7%)		5 (41.7%)	7 (58.3%)		4 (33.3%)	8 (66.7%)
Perineural invasion
No	54	24 (44.4%)	30 (55.6%)	0.535	31 (60.8%)	5 (39.2%)	0.917	34 (63.0%)	20 (37.0%)	0.293
Yes	9	5 (55.6%)	4 (44.4%)		5 (55.6%)	4 (44.4%)		4 (44.4%)	5 (55.6%)

*, p < 0.05; **, p < 0.01.